Consensus on the treatment of autoimmune bullous dermatoses: dermatitis herpetiformis and linear IgA bullous dermatosis - Brazilian Society of Dermatology

Dermatitis herpetiformis and linear IgA bullous dermatosis are autoimmune diseases that present with pruritic urticarial papules and plaques, with formation of vesicles and blisters of subepidermal location, mediated by IgA antibodies. Mucosal lesions are present only in linear IgA bullous dermatosis. The elaboration of this consensus consisted of a brief presentation of the different aspects of these dermatoses and, above all, of an updated literature review on the various therapeutic options that were discussed and compared with the authors’ experience, aiming at the treatment orientation of these diseases in Brazil. Dermatitis herpetiformis is a cutaneous manifestation of celiac disease, and can be controlled with a gluten-free diet and dapsone. On the other hand, linear IgA bullous dermatosis arises spontaneously or is triggered by drugs, and can be controlled with dapsone, but often requires the association of systemic corticosteroids and eventually immunosuppressants.

[1]  A. Porro,et al.  Adult linear IgA bullous dermatosis: report of three cases* , 2018, Anais brasileiros de dermatologia.

[2]  K. Kaukinen,et al.  Dermatitis Herpetiformis: A Common Extraintestinal Manifestation of Coeliac Disease , 2018, Nutrients.

[3]  K. Kridin Subepidermal autoimmune bullous diseases: overview, epidemiology, and associations , 2018, Immunologic research.

[4]  J. Zone,et al.  Rituximab Treatment for Recalcitrant Dermatitis Herpetiformis , 2017, JAMA dermatology.

[5]  K. Kaukinen,et al.  Dermatitis herpetiformis: a cutaneous manifestation of coeliac disease , 2017, Annals of medicine.

[6]  A. Porro,et al.  Vancomycin-associated linear IgA disease mimicking toxic epidermal necrolysis* , 2016, Anais brasileiros de dermatologia.

[7]  E. Antiga,et al.  The diagnosis and treatment of dermatitis herpetiformis , 2015, Clinical, cosmetic and investigational dermatology.

[8]  D. Sanders,et al.  The gluten-free diet and its current application in coeliac disease and dermatitis herpetiformis , 2015, United European gastroenterology journal.

[9]  A. Jakes,et al.  Dermatitis herpetiformis , 2014, BMJ : British Medical Journal.

[10]  G. Wozel,et al.  Dapsone in dermatology and beyond , 2013, Archives of Dermatological Research.

[11]  J. Roujeau,et al.  Linear IgA bullous dermatosis: comparison between the drug‐induced and spontaneous forms , 2013, The British journal of dermatology.

[12]  V. Aoki,et al.  Linear IgA bullous dermatosis: report of an exuberant case* , 2013, Anais brasileiros de dermatologia.

[13]  L. Borradori,et al.  Acral Purpura as Leading Clinical Manifestation of Dermatitis Herpetiformis: Report of Two Adult Cases with a Review of the Literature , 2013, Dermatology.

[14]  L. Kotze Dermatitis herpetiformis, the celiac disease of the skin! , 2013, Arquivos de gastroenterologia.

[15]  K. Kaukinen,et al.  Reduced mortality in dermatitis herpetiformis: a population‐based study of 476 patients , 2012, The British journal of dermatology.

[16]  D. Massi,et al.  A further case of subacute prurigo‐like linear IgA bullous dermatosis: growing evidence of a new subset , 2012, International journal of dermatology.

[17]  L. Sagi,et al.  [Rituximab (Mabthera) for treatment of rare autoimmune bullous skin disorders]. , 2012, Harefuah.

[18]  V. Venning Linear IgA disease: clinical presentation, diagnosis, and pathogenesis. , 2012, Immunology and allergy clinics of North America.

[19]  M. Solaymani-Dodaran,et al.  The long‐term risk of malignancy following a diagnosis of coeliac disease or dermatitis herpetiformis: a cohort study , 2012, Alimentary pharmacology & therapeutics.

[20]  S. Ng,et al.  Management of linear IgA disease. , 2011, Dermatologic clinics.

[21]  R. Hall,et al.  Management of dermatitis herpetiformis. , 2011, Dermatologic clinics.

[22]  J. A. Barclay,et al.  Dapsone-Induced Methemoglobinemia: a Primer for Clinicians , 2011, The Annals of pharmacotherapy.

[23]  R. Hall,et al.  Pathophysiology of dermatitis herpetiformis: a model for cutaneous manifestations of gastrointestinal inflammation. , 2011, Dermatologic clinics.

[24]  S. Kárpáti An exception within the group of autoimmune blistering diseases: dermatitis herpetiformis, the gluten-sensitive dermopathy. , 2011, Dermatologic clinics.

[25]  D. Bolotin,et al.  Dermatitis herpetiformis: Part II. Diagnosis, management, and prognosis , 2011 .

[26]  S. Steinberg,et al.  Remission in dermatitis herpetiformis: a cohort study. , 2011, Archives of dermatology.

[27]  J. E. Herrero-González Guía clínica de diagnóstico y tratamiento de la dermatitis herpetiforme , 2010 .

[28]  A. Karaa,et al.  Linear IgA bullous dermatosis: the more frequent bullous dermatosis of children. , 2010, Dermatology online journal.

[29]  Valeria Aoki,et al.  Imunofluorescência direta e indireta , 2010 .

[30]  E. Antiga,et al.  Guidelines for the diagnosis and treatment of dermatitis herpetiformis , 2009, Journal of the European Academy of Dermatology and Venereology : JEADV.

[31]  R. Hubbard,et al.  No increase in risk of fracture, malignancy or mortality in dermatitis herpetiformis: a cohort study , 2008, Alimentary pharmacology & therapeutics.

[32]  P. Hill,et al.  Coeliac disease: a biopsy is not always necessary for diagnosis , 2008, Alimentary pharmacology & therapeutics.

[33]  Antônio José Tebcherani,et al.  Dermatose por IgA linear induzida pela gestação , 2008 .

[34]  R. Rogers,et al.  Clinical, pathologic, and immunopathologic features of dermatitis herpetiformis: review of the Mayo Clinic experience *, † , 2007, International journal of dermatology.

[35]  C. Talhari,et al.  Ocular linear IgA disease resulting in blindness. , 2006, Archives of dermatology.

[36]  Michelle A. Pipitone,et al.  Immunobullous diseases. , 2005, Journal of the American Academy of Dermatology.

[37]  A. Cooper,et al.  Sulfasalazine and dermatitis herpetiformis , 2005, The Australasian journal of dermatology.

[38]  Arthur Rook,et al.  Rook's Textbook of Dermatology , 2004 .

[39]  M. Bardella,et al.  Long‐term remission in patients with dermatitis herpetiformis on a normal diet , 2003, The British journal of dermatology.

[40]  J. Murray,et al.  Dermatitis herpetiformis , 2003, International journal of dermatology.

[41]  L. Fry Dermatitis herpetiformis: problems, progress and prospects. , 2002, European journal of dermatology : EJD.

[42]  F. Wojnarowska,et al.  Linear IgA disease: successful treatment with erythromycin , 2002, Clinical and experimental dermatology.

[43]  C. Cockerell,et al.  Characterization of a Subgroup of Patients With Dermatitis Herpetiformis With Nonclassical Histologic Features. , 2002, The American Journal of dermatopathology.

[44]  D. Zillikens BP180 as the common autoantigen in blistering diseases with different clinical phenotypes. , 2002, The Keio journal of medicine.

[45]  L. Davis,et al.  Localized linear IgA disease responding to colchicine , 2002, International journal of dermatology.

[46]  D. Mutasim,et al.  Immunofluorescence in dermatology. , 2001, Journal of the American Academy of Dermatology.

[47]  J. Zone Clinical Spectrum, Pathogenesis and Treatment of Linear IgA Bullous Dermatosis , 2001, The Journal of dermatology.

[48]  M. Marinkovich,et al.  Linear IgA bullous dermatosis. , 2001, Clinics in dermatology.

[49]  L. Morrison,et al.  Direct immunofluorescence microscopy in the diagnosis of autoimmune bullous dermatoses. , 2001, Clinics in dermatology.

[50]  M. Stiller,et al.  Dapsone and sulfones in dermatology: overview and update. , 2001, Journal of the American Academy of Dermatology.

[51]  A. Ormerod,et al.  Dermatitis herpetiformis effectively treated with heparin, tetracycline and nicotinamide , 2000, Clinical and experimental dermatology.

[52]  J. Zone,et al.  Linear IgA bullous dermatosis , 1999, International journal of dermatology.

[53]  Bianchi,et al.  The role of lymphocytes, granulocytes, mast cells and their related cytokines in lesional skin of linear IgA bullous dermatosis , 1999, The British journal of dermatology.

[54]  J. Scott,et al.  The blistering diseases. , 1998, The Medical clinics of North America.

[55]  J. Garioch,et al.  Protective effect of gluten‐free diet against development of lymphoma in dermatitis herpetiformis , 1996, The British journal of dermatology.

[56]  E. Bröcker,et al.  Incidence of autoimmune subepidermal blistering dermatoses in a region of central Germany. , 1995, Archives of dermatology.

[57]  B. K. Park,et al.  Cimetidine improves the therapeutic/toxic ratio of dapsone in patients on chronic dapsone therapy , 1995, The British journal of dermatology.

[58]  J. Garioch,et al.  25 years' experience of a gluten‐free diet in the treatment of dermatitis herpetiformis , 1994, The British journal of dermatology.

[59]  M. Black,et al.  Chronic bullous disease of childhood and linear IgA disease of adults are IgA1‐mediated diseases , 1994, The British journal of dermatology.

[60]  M. Coleman Dapsone: modes of action, toxicity and possible strategies for increasing patient tolerance , 1993, The British journal of dermatology.

[61]  T. Starink,et al.  Efficacy of cyclosporine in two patients with dermatitis herpetiformis resistant to conventional therapy. , 1993, Journal of the American Academy of Dermatology.

[62]  K. Neldner,et al.  Successful treatment of dermatitis herpetiformis with tetracycline and nicotinamide in a patient unable to tolerate dapsone. , 1993, Journal of the American Academy of Dermatology.

[63]  D. Fivenson,et al.  Linear IgA bullous dermatosis: successful treatment with tetracycline and nicotinamide. , 1992, Journal of the American Academy of Dermatology.

[64]  G. Guyatt,et al.  The protective effect of vitamin E on the hemolysis associated with dapsone treatment in patients with dermatitis herpetiformis. , 1992, Archives of dermatology.

[65]  B. G. Goldstein,et al.  Sulfasalazine in dermatitis herpetiformis. , 1990, Journal of the American Academy of Dermatology.

[66]  G. Kahn Dapsone is safe during pregnancy. , 1985, Journal of the American Academy of Dermatology.

[67]  K. Ljunghall,et al.  Dermatitis herpetiformis: effect of gluten-restricted and gluten-free diet on dapsone requirement and on IgA and C3 deposits in uninvolved skin. , 1983, Acta dermato-venereologica.

[68]  L. Fry,et al.  Long term follow‐up of dermatitis herpetiformis with and without dietary gluten withdrawal , 1982, The British journal of dermatology.

[69]  D. Silvers,et al.  Treatment of dermatitis herpetiformis with colchicine. , 1980, Archives of dermatology.

[70]  A. Almeida,et al.  Dermatose bolhosa por IgA linear , 2019, Revista Médica de Minas Gerais.

[71]  M. Marinkovich,et al.  Linear immunoglobulin A bullous dermatosis. , 2012, Clinics in dermatology.

[72]  S. Kárpáti,et al.  Dermatitis herpetiformis. , 2012, Clinics in dermatology.

[73]  D. Bolotin,et al.  Dermatitis herpetiformis , 2011 .

[74]  C. Bédane,et al.  [Dermatitis herpetiformis. Guidelines for the diagnosis and treatment. Centres de référence des maladies bulleuses auto-immunes. Société Française de Dermatologie]. , 2011, Annales de dermatologie et de vénéréologie.

[75]  S. Uzun,et al.  Dermatitis herpetiformis in a patient receiving infliximab for ankylosing spondylitis. , 2008, European journal of dermatology : EJD.

[76]  C. Talhari,et al.  Ocular linear IgA disease resulting in blindness. Commentary , 2006 .

[77]  H. Kerl,et al.  UV light-induced linear IgA dermatosis. , 2004, Journal of the American Academy of Dermatology.

[78]  Y. Tay,et al.  Treatment of Linear IgA Bullous Dermatosis of Childhood with Colchicine , 1999, Pediatric dermatology.

[79]  D. Miyamoto,et al.  Longitudinal Evaluation of Manual Lymphatic Drainage For , 2022 .